IP Verse

Apotex Inc. et al. vs Regeneron Pharmaceuticals, Inc.

The detailed information for PTAB case with proceeding number IPR2022-01524 filed by Apotex Inc. et al. against Regeneron Pharmaceuticals, Inc. on Sep 9, 2022. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Case Details

Proceeding Number
IPR2022-01524
Filing Date
Sep 9, 2022
Petitioner
Apotex Inc. et al.
Respondent
Regeneron Pharmaceuticals, Inc.
Status
Institution Denied
Respondent Application Number
17352892
Respondent Tech Center
1600
Respondent Patent Number
11253572
Institution Decision Date
Mar 10, 2023
Termination Date
Mar 10, 2023

Proceeding Documents

The table below shows documents filed in the case, listing each document name, filing date, document type, and filing party. Tracking these filings indicates the activity of the parties involved in the case, and the types of documents filed can provide insights into the legal strategies being employed.


Document NameFiling DateCategoryFiling Party

Alert me when new update on this case

Denying Institution of Inter Partes Review 35 U.S.C. § 314

Mar 10, 2023PAPERBOARD

Patent Owner's Updated Mandatory Notices

Jan 26, 2023PAPERPATENT OWNER

EXPUNGED

Dec 23, 2022PAPERPATENT OWNER

Patent Owner Preliminary Response

Dec 23, 2022PAPERPATENT OWNER

Scheduling Order, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Expert Declaration of Richard Manning, Ph.D. (Redacted Copy)

Dec 23, 2022EXHIBITPATENT OWNER

Decision, Mylan Pharms. Inc. v. Regeneron Pharms., Inc., IPR2021-00881

Dec 23, 2022EXHIBITPATENT OWNER

Decision, Mylan Pharms. Inc. v. Regeneron Pharms., Inc., IPR2021-00880

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,828,345 B2

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 9,669,069

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,130,681

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 1 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 2 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 3 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 4 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 5 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 6 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,857,205 (Part 7 of 7)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 10,888,601

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent Application 17/072,417

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent Application 17/112,404

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent Application 17/350,958

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 11,253,572 (Part 1 of 2)

Dec 23, 2022EXHIBITPATENT OWNER

File History of U.S. Patent 11,253,572 (Part 2 of 2)

Dec 23, 2022EXHIBITPATENT OWNER

Mylan's Answer, Defenses, and Counterclaims to Plaintiff’s Complaint, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Complaint, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Regeneron’s Response to Mylan’s Post-Hearing Supplement, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Regeneron’s Stipulation Regarding Case Narrowing and Injunctive Relief, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Dec. 12. 2022 Letter to Neil B. McLaughlin from Thomas S. Fletcher Regarding Narrowing the Case, Mylan Pharms. Inc. v. Regeneron Pharms, Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Preliminary Response of Patent Owner Regeneron Pharmaceuticals, Inc., Mylan Pharms. Inc. v. Regeneron Pharms., Inc., IPR2022-01225

Dec 23, 2022EXHIBITPATENT OWNER

Jaffe et al., Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid, 123 OPHTHALMOLOGY 1856 (2016)

Dec 23, 2022EXHIBITPATENT OWNER

Expert Declaration of Lucian V. Del Priore, M.D., Ph.D. (Redacted Copy), Mylan Pharms. Inc. v. Regeneron Pharms, Inc., IPR2021-00881, Exhibit No. 2048

Dec 23, 2022EXHIBITPATENT OWNER

Eylea (aflibercept) Injection label, revised May 2016

Dec 23, 2022EXHIBITPATENT OWNER

Transcript Jan. 20, 2022 Deposition of Thomas Albini, M.D. in Mylan Pharms. Inc. v. Regeneron Pharms, Inc., IPR2021-00880 & IPR2021-00881

Dec 23, 2022EXHIBITPATENT OWNER

CENTER FOR DRUG EVALUATION & RESEARCH, Medical Review, BLA No. 125156

Dec 23, 2022EXHIBITPATENT OWNER

Mansour et al., Long-term Visual Outcomes of Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization, 148 AM. J. OPTHAMOLOGY. 310 (2009)

Dec 23, 2022EXHIBITPATENT OWNER

Lott et al., Bevacizumab in Inflammatory Eye Disease, 148 AM. J. OPTHAMOLOGY. 711 (2009)

Dec 23, 2022EXHIBITPATENT OWNER

Motion Requesting Expedited Status Conference, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Regeneron’s Opening Claim Construction Brief, Regeneron Pharms., Inc. v. Mylan Pharms. Inc., Case No. 1:22-cv-00061-TSK

Dec 23, 2022EXHIBITPATENT OWNER

Petition for Inter Partes Review of U.S. Patent No. 9,669,069 B2, Mylan Pharms. Inc. v. Regeneron Pharms., Inc., IPR2021-00880

Dec 23, 2022EXHIBITPATENT OWNER

Petition for Inter Partes Review of U.S. Patent No. 9,669,069 B2, Apotex Inc. v. Regeneron Pharms., Inc., IPR2022-00301

Dec 23, 2022EXHIBITPATENT OWNER

Petition for Inter Partes Review of U.S. Patent No. 9,254,338 B2, Mylan Pharms. Inc. v. Regeneron Pharms., Inc, IPR2021-00881

Dec 23, 2022EXHIBITPATENT OWNER

etition for Inter Partes Review of U.S. Patent No. 9,254,338 B2, Apotex Inc. v. Regeneron Pharms., Inc., IPR2022-00298

Dec 23, 2022EXHIBITPATENT OWNER

Patent Owner's Power of Attorney

Oct 5, 2022PAPERPATENT OWNER

Patent Owner's Mandatory Notices

Oct 5, 2022PAPERPATENT OWNER

Notice: Notice filing date accorded

Sep 28, 2022PAPERBOARD

1001 - 572 patent

Sep 9, 2022EXHIBITPETITIONER

1002 - Expert Declaration of Angelo P. Tanna, M.D.

Sep 9, 2022EXHIBITPETITIONER

1003 - CV of Angelo P. Tanna, M.D.

Sep 9, 2022EXHIBITPETITIONER

1004 - Holash

Sep 9, 2022EXHIBITPETITIONER

1005 - Nguyen-2009

Sep 9, 2022EXHIBITPETITIONER

1006 - Dixon

Sep 9, 2022EXHIBITPETITIONER

1007 - Adis

Sep 9, 2022EXHIBITPETITIONER

1008 - Semeraro

Sep 9, 2022EXHIBITPETITIONER

1009 - Regeneron (8-May-2008)

Sep 9, 2022EXHIBITPETITIONER

1010 - NCT-795

Sep 9, 2022EXHIBITPETITIONER

1011 - NCT-377

Sep 9, 2022EXHIBITPETITIONER

1012 - Monthly-Dosing-Patents

Sep 9, 2022EXHIBITPETITIONER

1013 - 338 FH

Sep 9, 2022EXHIBITPETITIONER

1014 - Heier-2012

Sep 9, 2022EXHIBITPETITIONER

1015 - Heier-2009

Sep 9, 2022EXHIBITPETITIONER

1016 - 2009 10-Q

Sep 9, 2022EXHIBITPETITIONER

1017 - Bayer (8-May-2008)

Sep 9, 2022EXHIBITPETITIONER

1018 - Brown

Sep 9, 2022EXHIBITPETITIONER

1019 - Lucentis

Sep 9, 2022EXHIBITPETITIONER

1020 - Reichert

Sep 9, 2022EXHIBITPETITIONER

1021 - History-ClinicalTrials.gov

Sep 9, 2022EXHIBITPETITIONER

1022 - Wayback-Affidavit-038

Sep 9, 2022EXHIBITPETITIONER

1023 - Nguyen-2006

Sep 9, 2022EXHIBITPETITIONER

1024 - Patent Owner Exhibit 2050 in IPR2021-00881

Sep 9, 2022EXHIBITPETITIONER

1025 - Hecht

Sep 9, 2022EXHIBITPETITIONER

1026 - Rosenfeld

Sep 9, 2022EXHIBITPETITIONER

1027 - Randolph

Sep 9, 2022EXHIBITPETITIONER

1028 - Fraser

Sep 9, 2022EXHIBITPETITIONER

1029 - Saishin

Sep 9, 2022EXHIBITPETITIONER

1030 - Heier-2012 Appendix

Sep 9, 2022EXHIBITPETITIONER

1031 - FDA Guidance for Industry

Sep 9, 2022EXHIBITPETITIONER

1032 - Heimann-2007

Sep 9, 2022EXHIBITPETITIONER

1033 - Jager-2004

Sep 9, 2022EXHIBITPETITIONER

1034 - NIH AMD

Sep 9, 2022EXHIBITPETITIONER

1035 - NIH DR

Sep 9, 2022EXHIBITPETITIONER

1036 - Regeneron (28-April-2008)

Sep 9, 2022EXHIBITPETITIONER

1037 - Ferrara-2005

Sep 9, 2022EXHIBITPETITIONER

1038 - Rudge

Sep 9, 2022EXHIBITPETITIONER

1039 - NCT-973

Sep 9, 2022EXHIBITPETITIONER

1041 - Regeneron (27-March-2007)

Sep 9, 2022EXHIBITPETITIONER

1042 - Regeneron (2-August-2007)

Sep 9, 2022EXHIBITPETITIONER

1043 - Regeneron (19-August-2008)

Sep 9, 2022EXHIBITPETITIONER

1044 - Regeneron (28-September-2008)

Sep 9, 2022EXHIBITPETITIONER

1045 - Regeneron (30-April-2009)

Sep 9, 2022EXHIBITPETITIONER

1046 - Regeneron (14-September-2009)

Sep 9, 2022EXHIBITPETITIONER

1047 - Regeneron (18-February-2010)

Sep 9, 2022EXHIBITPETITIONER

1048 - Bayer (19-August-2008)

Sep 9, 2022EXHIBITPETITIONER

1049 - Campochiaro

Sep 9, 2022EXHIBITPETITIONER

1050 - Hayes

Sep 9, 2022EXHIBITPETITIONER

1051 - Anderson

Sep 9, 2022EXHIBITPETITIONER

1052 - Ciulla

Sep 9, 2022EXHIBITPETITIONER

1053 - Ni

Sep 9, 2022EXHIBITPETITIONER

1054 - Zarbin

Sep 9, 2022EXHIBITPETITIONER

1055 - Corporate Finance Institute

Sep 9, 2022EXHIBITPETITIONER

1056 - Schneider

Sep 9, 2022EXHIBITPETITIONER

1057 - Kuepper

Sep 9, 2022EXHIBITPETITIONER

1058 - Zucchi

Sep 9, 2022EXHIBITPETITIONER

Petition for IPR - US 11,253,572

Sep 9, 2022PAPERPETITIONER

Petitioner's Power of Attorney

Sep 9, 2022PAPERPETITIONER